University of Iceland   Report issue

Academic/Hospital Phase 2 Phase 4
Founded: Reykjavik Iceland (1911)

Organization Overview

First Clinical Trial
2004
NCT02273895
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Landspitali - The National University Hospital of Iceland, Reykjavik | Landspitali University Hospital | Landspitali University Hospital Reykjavik LSH Iceland | University of Iceland

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Drug Overdose (Phase 2)

Food Hypersensitivity (Phase 2)

Hypersensitivity (Phase 2)

Multiple Myeloma (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Shock (Phase 2)

Shock, Septic (Phase 2)

Smoldering Multiple Myeloma (Phase 2)

Tuberculosis (Phase 2)

Tuberculosis, Pulmonary (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 11
  • # of Trial APIs: 16